BioCryst Pharmaceuticals
American pharmaceutical company
BCRX Nasdaq
ISIN US09058V1035 SEC CIK 882796 LEI 549300Z0INP1Z5NP6J59
Follow BioCryst Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$180.3M
+13.1% vs same quarter last year
Net income
$37.9M
+193.9% vs same quarter last year
EPS, diluted
$0.14
+133.3% vs same quarter last year
Operating cash flow
$33M
−20.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $874.8M | $263.9M |
| FY24 | $450.7M | −$88.9M |
| FY23 | $331.4M | −$226.5M |
| FY22 | $270.8M | −$247.1M |
| FY21 | $157.2M | −$184.1M |
| FY20 | $17.8M | −$182.8M |
| FY19 | $48.8M | −$108.9M |
| FY18 | $20.7M | −$101.3M |
| FY17 | $25.2M | −$65.8M |
| FY16 | $26.4M | −$55.1M |
| FY15 | $48.3M | −$43M |
| FY14 | $13.6M | −$45.2M |
| FY13 | $17.3M | −$30.1M |
| FY12 | $26.3M | −$39.1M |
| FY11 | $19.6M | −$56.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 97.8% | 39% | 30.2% |
| FY24 | 97.3% | −0.6% | −19.7% |
| FY23 | 98.6% | −31.3% | −68.4% |
| FY22 | 97.6% | −54.8% | −91.2% |
| FY21 | 95.4% | −113.1% | −117.1% |
| FY20 | 91.3% | −981.1% | −1026.4% |
| FY19 | 92.4% | −203.7% | −223% |
| FY18 | - | −456.2% | −490.3% |
| FY17 | 95.5% | −227.9% | −261.2% |
| FY16 | 91.3% | −184.4% | −209.3% |
| FY15 | 97.2% | −81.7% | −89.1% |
| FY14 | 100% | −336.4% | −332.1% |
| FY13 | - | −177.2% | −173.7% |
| FY12 | - | −128.9% | −148.6% |
| FY11 | - | −252.4% | −289.9% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $344.9M |
| FY24 | −$53.1M |
| FY23 | −$97.3M |
| FY22 | −$163.2M |
| FY21 | −$144.5M |
| FY20 | −$135.6M |
| FY19 | −$89.9M |
| FY18 | −$92.9M |
| FY17 | −$41.5M |
| FY16 | −$58.7M |
| FY15 | −$18.2M |
| FY14 | −$38.7M |
| FY13 | −$26.6M |
| FY12 | −$37.5M |
| FY11 | −$32.3M |
- BioCryst Pharmaceuticals
- Healthcare median
Show the numbers
| Year | BioCryst Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 30.2% | −30.6% |
| FY24 | −19.7% | −47% |
| FY23 | −68.4% | −58% |
| FY22 | −91.2% | −80.4% |
| FY21 | −117.1% | −71.8% |
| FY20 | −1026.4% | −62.2% |
| FY19 | −223% | −46.2% |
| FY18 | −490.3% | −49.6% |
| FY17 | −261.2% | −45.9% |
| FY16 | −209.3% | −36% |
| FY15 | −89.1% | −37.8% |
| FY14 | −332.1% | −35.5% |
| FY13 | −173.7% | −37.1% |
| FY12 | −148.6% | −29.1% |
| FY11 | −289.9% | −27.9% |